Skip to content

Sleep Disturbances as a Non-traditional Risk Factor in CKD-Actigraphy

Sleep Disturbances as a Non-traditional Risk Factor in CKD-Wrist Actigraphy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00817674
Acronym
CRIC
Enrollment
353
Registered
2009-01-06
Start date
2007-11-30
Completion date
2010-10-31
Last updated
2013-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Sleep Loss

Keywords

CKD, Kidney Disease, poor sleep, CKD progression

Brief summary

To test if usual at home night time sleep duration as measured with activity monitors and questionnaires will predict changes in kidney function as measured by kidney filtration rate and of cardiovascular function as measured by C-reactive protein in the blood. The study will explore the role of decreased sleep time or decreased sleep quality as a non-traditional risk factor for the progression of CKD and for the development of cardiovascular disease in CKD.

Interventions

None listed

Sponsors

University of Illinois at Chicago
CollaboratorOTHER
Case Western Reserve University
CollaboratorOTHER
University of Chicago
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 74 Years
Healthy volunteers
Yes

Inclusion criteria

* Mild to Moderate CKD * Healthy controls age and gender matched to CKD subjects * Regular bedtimes of at least 6h/night, sedentary lifestyle

Exclusion criteria

* Diabetes * Current or previous dialysis for more than 1 month * Uncontrolled hypertension * Heart failure * Liver disease * HIV * Hemoglobin \< 10.5 g/dl * Treatment with EProcrit, Epogen, or Aranesp * Bone or organ transplant, * Use of immunosuppressive drugs within past 6 months * Current oral contraceptive use * Current pregnancy * Chemotherapy for malignancy within past 2 years

Design outcomes

Primary

MeasureTime frame
CKD progression as measured by changes in GFR and cardiovascular risk as measured by CRP over a 5 year period5 years

Secondary

MeasureTime frame
insulin resistance5 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026